Rovaleucel

DB18691InvestigationalCell transplant therapies

Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.

Mechanism: Pharmacologically active on Adenosine receptor A2a and Transcriptional coactivator YAP1
Curator reviewed
Code names: TT-10

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rovaleucel, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.